No risk factors have been identified for vaccine-induced immune thrombotic thrombocytopenia (VITT) so far. The aim of this study was to identify human leucocyte antigen (HLA) alleles potentially associated with VITT susceptibility. Specific HLA class II alleles were detected with significantly higher frequency in VITT patients compared with Italian controls: DPB1*17:01, DQA1*05:01, and DRB1*11:04. In silico analysis revealed increased affinity of DRB1*11:04 for a platelet factor 4 (PF4)-derived peptide, ITSLEVIKA, that contains two amino acids present in the specific binding site of anti-PF4 antibodies from VITT patients. Our findings show for the first time a genetic predisposition to developing anti-PF4 antibodies in response to Ad-vector vaccines.
Association of human leucocyte antigen loci with vaccine-induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4-derived peptides and MHC-II / Petito, Eleonora; Bury, Loredana; Antunes Heck, Lilian; Sadler, Brooke; De Candia, Erica; Podda, Gian Marco; Falanga, Anna; Stefanini, Lucia; Boccatonda, Andrea; Sciancalepore, Patrizia; Florio, Igor; Imbalzano, Egidio; Marcucci, Rossella; Noris, Patrizia; Panella, Marta; Santoro, Rita Carlotta; Turi, Maria Costanza; Vaudo, Gaetano; Di Paola, Jorge; Rondina, Matthew T; Gresele, Paolo. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - (2024). [10.1111/bjh.19838]
Association of human leucocyte antigen loci with vaccine-induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4-derived peptides and MHC-II
Podda, Gian Marco;Stefanini, Lucia;
2024
Abstract
No risk factors have been identified for vaccine-induced immune thrombotic thrombocytopenia (VITT) so far. The aim of this study was to identify human leucocyte antigen (HLA) alleles potentially associated with VITT susceptibility. Specific HLA class II alleles were detected with significantly higher frequency in VITT patients compared with Italian controls: DPB1*17:01, DQA1*05:01, and DRB1*11:04. In silico analysis revealed increased affinity of DRB1*11:04 for a platelet factor 4 (PF4)-derived peptide, ITSLEVIKA, that contains two amino acids present in the specific binding site of anti-PF4 antibodies from VITT patients. Our findings show for the first time a genetic predisposition to developing anti-PF4 antibodies in response to Ad-vector vaccines.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
